Group 1 - Sana Biotechnology, Inc. has priced its underwritten public offering of 20,895,522 shares of common stock at $3.35 per share and pre-funded warrants to purchase 1,492,537 shares at $3.3499 per warrant [1] - The gross proceeds from the offering are expected to be approximately $75.0 million before deducting underwriting discounts and commissions [1] - The offering is expected to close on or about August 8, 2025, subject to customary closing conditions [1] Group 2 - Morgan Stanley, Goldman Sachs & Co. LLC, BofA Securities, and TD Cowen are acting as joint book-running managers for the offering [2] - The offering is being made pursuant to a Registration Statement on Form S-3, which has been declared effective by the SEC [3] - A final prospectus supplement and accompanying prospectus will be filed with the SEC [3] Group 3 - Sana Biotechnology, Inc. is focused on creating and delivering engineered cells as medicines for patients [5] - The company has operations in Seattle, WA, Cambridge, MA, and South San Francisco, CA [5]

Core Viewpoint - Sana Biotechnology, Inc. has announced a public offering of $75 million in common stock and pre-funded warrants, with an additional option for underwriters to purchase up to $11.25 million more [1][2]. Group 1: Offering Details - The public offering consists of $75 million in shares of common stock and pre-funded warrants for certain investors [1]. - The underwriters will have a 30-day option to purchase an additional $11.25 million in shares [1]. - All shares and warrants will be sold by Sana, and the offering is subject to market conditions [1]. Group 2: Underwriters - Morgan Stanley, Goldman Sachs & Co. LLC, BofA Securities, and TD Cowen are acting as joint book-running managers for the offering [2]. Group 3: Regulatory Information - The offering is made under a Registration Statement on Form S-3, which has been declared effective by the SEC [3]. - A preliminary prospectus supplement will be filed to describe the terms of the offering, available through the SEC's website [3]. Group 4: Company Overview - Sana Biotechnology focuses on creating engineered cells as medicines for patients, with operations in Seattle, WA, Cambridge, MA, and South San Francisco, CA [5].